IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, the CML+CIGB-258 group showed a more remarkable decrease in IL-6 stained area (photo d1 and d2), a ~7.6% stained area, which was 67% smaller than the CML+PBS group, suggesting that an injection of CIGB-258 (0.9 μg, final 1 μM) was two times more effective in reducing the hepatic IL-6 level of CML-mediated inflammation than apoA-I (final 1 μM).